Danaher (NYSE:DHR) Given New $226.00 Price Target at Evercore ISI

Danaher (NYSE:DHR - Free Report) had its price objective decreased by Evercore ISI from $230.00 to $226.00 in a report released on Tuesday,Benzinga reports. Evercore ISI currently has an outperform rating on the conglomerate's stock.

Several other research firms have also recently weighed in on DHR. Wolfe Research cut their price objective on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. UBS Group reduced their price objective on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Barclays restated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. TD Cowen increased their price objective on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Finally, Jefferies Financial Group decreased their target price on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $248.00.

Danaher Trading Up 2.3%

Shares of DHR traded up $4.59 during mid-day trading on Tuesday, reaching $205.55. 3,021,398 shares of the company were exchanged, compared to its average volume of 3,500,356. Danaher has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market capitalization of $147.11 billion, a PE ratio of 39.91, a PEG ratio of 2.82 and a beta of 0.77. The business has a 50 day simple moving average of $195.77 and a two-hundred day simple moving average of $206.81.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. On average, analysts predict that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Insiders Place Their Bets

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Institutional Trading of Danaher

Institutional investors have recently added to or reduced their stakes in the stock. Bank Pictet & Cie Europe AG lifted its holdings in shares of Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after purchasing an additional 35,730 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Danaher by 28.0% in the fourth quarter. Proficio Capital Partners LLC now owns 2,566 shares of the conglomerate's stock valued at $589,000 after purchasing an additional 562 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its stake in shares of Danaher by 3.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after buying an additional 52 shares during the period. Moran Wealth Management LLC lifted its stake in shares of Danaher by 2.5% during the fourth quarter. Moran Wealth Management LLC now owns 2,413 shares of the conglomerate's stock valued at $554,000 after buying an additional 58 shares during the period. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Danaher by 4.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 102,311 shares of the conglomerate's stock valued at $23,486,000 after buying an additional 4,287 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.